Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Jan 21;195(2):161–169. doi: 10.1084/jem.20011171

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002, The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — Effect of anti-TRAIL mAb on spontaneous tumor development in p53^+/− mice. (A) p53^+/− B6 mice were administered intraperitoneally with anti-TRAIL mAb (circles) or isotype-matched control rat Ig (squares) every 5 d starting at 3 wk of age, and then observed for tumor development over the course of 24 mo. Difference between two groups was statistically significant (P < 0.05) as analyzed by unpaired Mann-Whitney U test. (B) Cell lines were originated from spontaneous sarcoma development in isotype-matched control rat Ig- or anti-TRAIL mAb-treated p53^+/− mice. Then, their susceptibility to TRAIL-mediated cytotoxicity was determined as described in Fig. 2 after the preincubated with (solid black bars) or without (gray bars) IFN-γ for 24 h. Data are represented as the mean ± SD of triplicate samples at an E/T = 10. The cytotoxic activity of mock-transfected 2PK-3 cells against all tumor cells was <2% (data not shown).

Figure 7. — Effect of anti-TRAIL mAb on spontaneous tumor development in p53^+/− mice. (A) p53^+/− B6 mice were administered intraperitoneally with anti-TRAIL mAb (circles) or isotype-matched control rat Ig (squares) every 5 d starting at 3 wk of age, and then observed for tumor development over the course of 24 mo. Difference between two groups was statistically significant (P < 0.05) as analyzed by unpaired Mann-Whitney U test. (B) Cell lines were originated from spontaneous sarcoma development in isotype-matched control rat Ig- or anti-TRAIL mAb-treated p53^+/− mice. Then, their susceptibility to TRAIL-mediated cytotoxicity was determined as described in Fig. 2 after the preincubated with (solid black bars) or without (gray bars) IFN-γ for 24 h. Data are represented as the mean ± SD of triplicate samples at an E/T = 10. The cytotoxic activity of mock-transfected 2PK-3 cells against all tumor cells was <2% (data not shown).